- Home
- COCH vs EDSA Comparison
COCH vs EDSA Comparison
Compare COCH & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- EDSA
- Stock Information
- Founded
- COCH 1995
- EDSA 2015
- Country
- COCH United States
- EDSA Canada
- Employees
- COCH N/A
- EDSA N/A
- Industry
- COCH Blank Checks
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- EDSA Health Care
- Exchange
- COCH Nasdaq
- EDSA Nasdaq
- Market Cap
- COCH 20.9M
- EDSA 18.6M
- IPO Year
- COCH N/A
- EDSA N/A
- Fundamental
- Price
- COCH $0.71
- EDSA $1.75
- Analyst Decision
- COCH Strong Buy
- EDSA Strong Buy
- Analyst Count
- COCH 1
- EDSA 2
- Target Price
- COCH $9.50
- EDSA $13.00
- AVG Volume (30 Days)
- COCH 552.0K
- EDSA 906.5K
- Earning Date
- COCH 10-31-2025
- EDSA 12-12-2025
- Dividend Yield
- COCH N/A
- EDSA N/A
- EPS Growth
- COCH N/A
- EDSA N/A
- EPS
- COCH N/A
- EDSA N/A
- Revenue
- COCH $222,000.00
- EDSA N/A
- Revenue This Year
- COCH $3.66
- EDSA N/A
- Revenue Next Year
- COCH $31.19
- EDSA N/A
- P/E Ratio
- COCH N/A
- EDSA N/A
- Revenue Growth
- COCH N/A
- EDSA N/A
- 52 Week Low
- COCH $0.70
- EDSA $1.55
- 52 Week High
- COCH $2.32
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- COCH 38.19
- EDSA 31.73
- Support Level
- COCH $0.70
- EDSA $1.90
- Resistance Level
- COCH $0.76
- EDSA $2.02
- Average True Range (ATR)
- COCH 0.06
- EDSA 0.21
- MACD
- COCH 0.00
- EDSA -0.08
- Stochastic Oscillator
- COCH 8.60
- EDSA 7.68
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.